Búsqueda de socios
Ref: RDRGB2025-OneHealthAMR
Descripción
A UK based drug discovery and development company has developed cysteamine bitartrate as a broad antibiotic potentiator for acute and chronic respiratory infections. Oral and IV forms of cysteamine bitartrate have been investigated in phase 2 and phase 3 clinical trials in cystic fibrosis and community acquired pneumonia. Cysteamine is an endogenous innate immune effector molecule developed therapeutically by NovaBiotics. The company is looking for partners for the first EUP OHAMR joint transnational call "Treatments and adherence to treatment protocols" on new treatments to tackle AMR.
Title
Cysteamine bitartrate as a broad antibiotic potentiator for acute and chronic respiratory infections
Abstract
For the EU programme – ONE HEALTH AMR (closing Feb 2nd 2026) my company are seeking 2 partners……………….
1-A partner with access to at least some priority bacterial pathogen panels and related bacteria mapped against resistance mechanisms to assist in fully profiling cysteamines adjuvant/resistance breaking/prevention profile
2 A partner with combination/chequerboard assay development experience. Depending on the pathogen, antibiotic and resistance mechanism, susceptibility assays will require further refinement from the standard chequerboard systems. This will be in terms of the end points at which effectiveness is assessed, the timing of introducing the antibiotic and cysteamine to better reflect the clinical setting.
1-A partner with access to at least some priority bacterial pathogen panels and related bacteria mapped against resistance mechanisms to assist in fully profiling cysteamines adjuvant/resistance breaking/prevention profile
2 A partner with combination/chequerboard assay development experience. Depending on the pathogen, antibiotic and resistance mechanism, susceptibility assays will require further refinement from the standard chequerboard systems. This will be in terms of the end points at which effectiveness is assessed, the timing of introducing the antibiotic and cysteamine to better reflect the clinical setting.